Last reviewed · How we verify
NCT07035392
Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
Phase 2 trial testing Adebrelimab in Adebrelimab (SHR-1316) in 32 participants. Not yet recruiting.
1 December 2026
Quick facts
| Lead sponsor | Zhangzhou Municipal Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 20 June 2025 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
Drugs / interventions tested
- Adebrelimab — full drug profile →
- chemotherapy (chemotherapy) — full drug profile →
Conditions studied
- Adebrelimab (SHR-1316) — all drugs for Adebrelimab (SHR-1316) →
- NSCLC — all drugs for NSCLC →
- Chemotherapy — all drugs for Chemotherapy →
Sponsor
Zhangzhou Municipal Hospital
Who can join
Adults 18 to 70, any sex, with Adebrelimab (SHR-1316) or NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single arm, prospective, multicenter clinical trial, and eligible patients will receive the following treatment regimen: Adebrelimab combined with chemotherapy.The study includes a screening period (from the signing of informed consent by the subjects to no more than 28 days before the first medication, imaging examinations are allowed to be performed within 28 days before the first medication, and tumor tissue biopsy is allowed to be archived within 6 months before the first medication), a treatment period (including neoadjuvant and surgical treatment), and a follow-up period (including safety follow-up and survival follow-up).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07035392
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Adebrelimab
Trials testing the same drug.
- NCT07398560 — Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lu · Phase 2 · not yet recruiting
- NCT07392541 — Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer · Phase 1, PHASE2 · recruiting
- NCT07266025 — Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-Hi · Phase 2 · not yet recruiting
- NCT06177522 — Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07241793 — Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metast · Phase 2 · recruiting
Other recruiting trials for Adebrelimab (SHR-1316)
Currently open trials in the same condition.
- NCT06607276 — Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE · Phase 2 · recruiting
- NCT06506292 — A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophagea · Phase 2 · recruiting
Other Zhangzhou Municipal Hospital trials
Trials by the same sponsor.
- NCT06478264 — A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma · Phase 2 · not yet recruiting
- NCT06458348 — Local Opera Viewing Combined Medical Gymnastics for Elderly PSCI · NA · not yet recruiting
- NCT06179017 — Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion · NA · active not recruiting
- NCT06505512 — A Study of Enterorenal Syndrome Assessed by Gastrointestinal Ultrasound Combined with Renal Artery Resistance Index · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07035392 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhangzhou Municipal Hospital
- Last refreshed: 25 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07035392.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing